Business Description
CV Sciences Inc
NAICS : 325411
SIC : 2833
ISIN : US1266541028
Total Employee Number:
44Description
CV Sciences Inc is a consumer wellness company specializing in nutraceuticals and plant-based foods products. It develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol. The company sells its products under tradenames, such as +PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox. The company's products are sold in a variety of market sectors, including nutraceutical, beauty care, and specialty foods. The company has one operating segment, which is the business of hemp-based CBD wellness products. Geographically, all of the company's revenue is generated from United States. The company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 | |||||
Equity-to-Asset | 0.24 | |||||
Debt-to-Equity | 0.8 | |||||
Debt-to-EBITDA | -0.94 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -17.55 | |||||
Beneish M-Score | -3.22 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -13.8 | |||||
3-Year EBITDA Growth Rate | 71.2 | |||||
3-Year EPS without NRI Growth Rate | 41.5 | |||||
3-Year FCF Growth Rate | 40.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.04 | |||||
9-Day RSI | 50.54 | |||||
14-Day RSI | 48.64 | |||||
3-1 Month Momentum % | -11.12 | |||||
6-1 Month Momentum % | -62.41 | |||||
12-1 Month Momentum % | -21.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.99 | |||||
Quick Ratio | 0.18 | |||||
Cash Ratio | 0.05 | |||||
Days Inventory | 228.09 | |||||
Days Sales Outstanding | 11.98 | |||||
Days Payable | 65.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.6 | |||||
Shareholder Yield % | -4.99 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 49.14 | |||||
Operating Margin % | -7.6 | |||||
Net Margin % | -15.74 | |||||
EBITDA Margin % | -10.52 | |||||
FCF Margin % | -4.1 | |||||
OCF Margin % | -3.86 | |||||
ROE % | -127.3 | |||||
ROA % | -28.53 | |||||
ROIC % | -31.71 | |||||
3-Year ROIIC % | 1616.83 | |||||
ROC (Joel Greenblatt) % | -90.79 | |||||
ROCE % | -75.35 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
PE Ratio without NRI | 19.5 | |||||
PS Ratio | 0.29 | |||||
PB Ratio | 2.79 | |||||
EV-to-EBIT | -3.75 | |||||
EV-to-Forward-EBIT | 53 | |||||
EV-to-EBITDA | -4.02 | |||||
EV-to-Forward-EBITDA | 1.19 | |||||
EV-to-Revenue | 0.42 | |||||
EV-to-Forward-Revenue | 0.39 | |||||
EV-to-FCF | -10.33 | |||||
Price-to-GF-Value | 0.65 | |||||
Price-to-Median-PS-Value | 0.28 | |||||
Earnings Yield (Greenblatt) % | -26.67 | |||||
FCF Yield % | -11.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CVSI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CV Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12.743 | ||
| EPS (TTM) ($) | - | ||
| Beta | 0.4699 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.35 | ||
| Volatility % | 174.28 | ||
| 14-Day RSI | 48.64 | ||
| 14-Day ATR ($) | 0.00313 | ||
| 20-Day SMA ($) | 0.020116 | ||
| 12-1 Month Momentum % | -21.52 | ||
| 52-Week Range ($) | 0.0145 - 0.1 | ||
| Shares Outstanding (Mil) | 225.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CV Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CV Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 68 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 67 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 16:30 | 0.02 (-0.44%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 0.02 (-0.44%) | ||
| General meeting for 2026 | 2026-06-02 10:00 | 0.03 (+8.59%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 16:30 | 0.03 (+0.95%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.03 (+0.95%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 16:30 | 0.03 (-3.24%) | ||
| Annual report for 2025 | 2026-03-26 | 0.03 (-3.24%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 0.03 (-3.24%) |
Show
Entries
CV Sciences Inc Frequently Asked Questions
What is CV Sciences Inc(CVSI)'s stock price today?
The current price of CVSI is $0.02. The 52 week high of CVSI is $0.10 and 52 week low is $0.01.
When is next earnings date of CV Sciences Inc(CVSI)?
The next earnings date of CV Sciences Inc(CVSI) is 2026-11-13 Est..
Does CV Sciences Inc(CVSI) pay dividends? If so, how much?
CV Sciences Inc(CVSI) does not pay dividend.
Press Release
Articles on CV Sciences Inc
CV Sciences Inc (CVSI) (Q2 2026) Earnings Call Highlights: Strategic Pivot to PlusHealth Amid Regulatory Shifts
Aug 17, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers